Rare Malignant Neoplasm
Conditions
Brief summary
The goal of this observational study is to collect structured data about diagnosis, treatment and follow-up of rare and highly complex neoplasms. The study has a rerospective part that will consist in gathering data on patients accessing IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di S. Orsola from 01/01/2000 to 28/09/2017 and a prospective one ranging from 29/09/2017 to 31/12/2025.
Interventions
OTHERdiagnosis, surgery, drugs for rare neoplasms
diagnostic and surgical procedures, drugs (pharmacological active substance, dose, regimen)
Sponsors
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with histologic diagnosis of rare or highly complex malignant neoplasm * informed consent
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of different malignant rare neoplasms | Throughout the lenght of study, an average of 10 years | Description of types of tumours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response rate (RR) | Throughout the lenght of study, an average of 10 years | Response rate to different treatments (surgery, drugs) |
| Local recurrence rate | Throughout the lenght of study, an average of 10 years | Incidence of local recurrence |
| Progression-free survival (PFS) | Throughout the lenght of study, an average of 10 years | Progression-free survival (PFS) assessed for different types of rare malignant neoplasms |
| Overall survival (OS) | Throughout the lenght of study, an average of 10 years | OS assessed for different types of rare malignant neoplasms |
Countries
Italy
Contacts
Primary ContactMaria A Pantaleo, MD
Outcome results
None listed